At the time of the present study, German reimbursement regulations required failure of ≥4 (EM) and ≥5 (CM) first-line migraine preventive medications due to either insufficient efficacy, adverse effects, or contraindications before initiation of a CGRP mAb therapy (15). This evidence concerns the gene CALCA and migraine disorder.